Phase 3 Clinical Trials With Primary Completion Dates in February 2016
This is a list of Phase 3 trials with primary completion dates in February 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|AGRX||Agile Therapeutics, Inc.||2016-02-01||Phase 3||NCT02158572||Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System|
|ALKS||Alkermes plc||2016-02-01||Phase 3||NCT02158533||A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study|
|AMPE||Ampio Pharmaceuticals, Inc.||2016-02-01||Phase 3||NCT02556710||Study to Evaluate the Efficacy And Safety Of An Intra-Articular Injection Of Ampionâ„¢ In Adults With Pain With Osteoarthritis Of The Knee|
|CPIX||Cumberland Pharmaceuticals Inc.||2016-02-01||Phase 3||NCT01451411||A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (VaprisolÂ®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia|
|CTIC||CTI BioPharma Corp.||2016-02-01||Phase 3||NCT02055781||Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia|
|EARS||Auris Medical Holding AG||2016-02-01||Phase 3||NCT02040194||AM-101 in the Treatment of Acute Tinnitus 3|
|MSTX||Mast Therapeutics, Inc.||2016-02-01||Phase 3||NCT01737814||Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)|
|THLD||Threshold Pharmaceuticals, Inc.||2016-02-01||Phase 3||NCT01746979||Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma|
|TTPH||Tetraphase Pharmaceuticals, Inc.||2016-02-01||Phase 3||NCT01978938||Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections|